AGEO, a recent large multicentric study, investigated the efficacy of fluoropyrimidine with and without oxaliplatin in a large cohort of MMR-deficient colon cancer patients, as MMR-deficient colon cancer is resistant to 5-fluorouracil adjuvant chemotherapy while preliminary data suggest chemosensitivity to oxaliplatin [153]. This evidence concerns the gene MRC1 and malignant colon neoplasm.